Lantheus (NASDAQ:LNTH) Upgraded to “Buy” at StockNews.com

StockNews.com upgraded shares of Lantheus (NASDAQ:LNTH) from a hold rating to a buy rating in a report released on Friday.

Several other equities analysts also recently weighed in on LNTH. Truist Financial reiterated a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a research report on Friday. JMP Securities lowered their target price on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 7th. Redburn Atlantic began coverage on Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price on the stock. Leerink Partners boosted their price objective on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research report on Thursday, July 11th. Finally, B. Riley boosted their price objective on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, Lantheus has a consensus rating of “Moderate Buy” and an average price target of $122.50.

Lantheus Price Performance

Shares of LNTH opened at $84.08 on Friday. The firm has a market capitalization of $5.85 billion, a P/E ratio of 13.99 and a beta of 0.51. The business has a fifty day moving average of $106.89 and a 200 day moving average of $96.26. Lantheus has a one year low of $50.20 and a one year high of $126.89.

Institutional Investors Weigh In On Lantheus

Hedge funds have recently made changes to their positions in the company. Signaturefd LLC lifted its position in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 92 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 208 shares in the last quarter. UMB Bank n.a. lifted its position in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after buying an additional 126 shares in the last quarter. Kathleen S. Wright Associates Inc. purchased a new stake in shares of Lantheus in the third quarter worth about $51,000. Finally, Nkcfo LLC purchased a new stake in shares of Lantheus in the second quarter worth about $47,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.